Lupin Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi 

IMT News Desk
IMT News Desk
· 2 min read
Lupin Limited has launched Atharv Ability, a world-class neuro-rehabilitation center in Delhi

Lupin Limited (Lupin) announced the launch of Atharv Ability, its world-class neuro-rehabilitation center in Naraina Vihar, Delhi, dedicated to delivering comprehensive, outcome-driven, specialized, and multidisciplinary care for adults and children with neurological disabilities, enhancing mobility, improving quality of life, and supporting long-term recovery. 

Atharv Ability stands at the forefront of advanced neurorehabilitation, combining clinical expertise, technological precision, and personalized care programs to bridge critical treatment gaps across a wide spectrum of conditions, including stroke, traumatic brain injury, spinal cord injury, Parkinson’s disease, multiple sclerosis, and pediatric neurological disorders such as cerebral palsy. 

Following the successful launch of its centers in Mumbai in 2023 and Hyderabad in 2024, Atharv Ability’s Delhi facility seeks to expand access to integrated, high-quality neuro-rehabilitation care in a region where such specialized services remain limited. 

Rajeev Sibal, President – India Region Formulations, Lupin, said, “Atharv Ability embodies this belief that healthcare must extend beyond treatment to sustained recovery, with personalized, patient‑focused care. This expansion underscores our belief that high-quality neurorehabilitation must be accessible, affordable, and standardized across India. 

Atharv Ability integrates advanced technologies with multidisciplinary care, featuring end-effector robotics for gait and hand training, AI-based balance and postural-control systems, and therapies spanning neuro-physiotherapy, occupational, speech and swallowing, cognitive-behavioral, aqua, visual and virtual-reality-based rehabilitation.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk